Table 4.
Stable disease ≥ + 6 months or partial response (PR) by RECIST and characterization by patient.
| Patient ID | Cancer type | Dose level | Best response by RECIST v1.0 | Number of prior systemic regimens | Duration of treatment (weeks) | PTEN mut | PIK3CA mut | RAS mut | RAF mut | P53 mut |
| 41 | Ocular melanoma | 2 | SD (−3%) | 4 | 36 | ND | N | ND | ND | ND |
| 50 | HR+, HER2- Breast | 3 | SD (−9%) | 9 | 43 | N | E542K | KRAS G12S | N | N |
| 73 | Mucoepidermoid Parotid Cancer | 5 | PR (--62%) | 1 | 19 | N | N | N | N | N |
| 101 | Endometroid ovarian carcinoma | 6 | PR (−50%) | 6 | 97 | N | N | N | N | N |
| 107 | Leiomyosarcoma | 6 | SD (−4%) | 7 | 29 | deletion | N | N | N | V147fs*23 |
| 120 | Vaginal Squamous Cell carcinoma | 9 | PR (−35%) | 8 | 50 | N | E545K, I391M | N | N | N |
| 138 | Clear cell carcinoma of kidney | 9 | SD (−16%) | 5 | 31 | I150fs*4 | N | N | N | N |
| 127 | Thymoma | 10 | SD (−16%) | 6 | 31 | N | N | N | N | N |
Abbreviations: mut, mutation; ND, not done; N, no; HR, hormone receptor; HER-2, human epidermal growth factor receptor 2.